期刊
JOURNAL OF CONTROLLED RELEASE
卷 304, 期 -, 页码 268-287出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2019.05.035
关键词
Drug delivery; Hybrid nanodelivery systems; Nanoparticles; Photodynamic therapy; Temoporfin
资金
- French Ligue Nationale contre le Cancer (CCIR-GE)
- Institut de Cancerologie de Lorraine
- Belarusian Republican Foundation for Fundamental Research (BRFFR) [M18MB-002]
- Ministry of Education of the Republc of Belarus
Enthusiasm for photodynamic therapy (PDT) as a promising technique to eradicate various cancers has increased exponentially in recent decades. The majority of clinically approved photosensitizers are hydrophobic in nature, thus, the effective delivery of photosensitizers at the targeted site is the main hurdle associated with PDT. Temoporfin (mTHPC, medicinal product name: Foscan (R)), is one of the most potent clinically approved photosensitizers, is not an exception. Successful temoporfin-PDT requires nanoscale delivery systems for selective delivery of photosensitizer. Over the last 25 years, the number of papers on nanoplatforms developed for mTHPC delivery such as conjugates, host-guest inclusion complexes, lipid-and polymer-based nanoparticles and carbon nanotubes is burgeoning. However, none of them appeared to be ultimate. The present review offers the description of different challenges and achievements in nanoparticle-based mTHPC delivery focusing on the synergetic combination of various nano-platforms to improve temoporfin delivery at all stages of biodistribution. Furthermore, the association of different nanoparticles in one nanoplatform might be considered as an advanced strategy allowing the combination of several treatment modalities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据